<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04645966</url>
  </required_header>
  <id_info>
    <org_study_id>C3511002</org_study_id>
    <secondary_id>2020-000948-60</secondary_id>
    <nct_id>NCT04645966</nct_id>
  </id_info>
  <brief_title>A Clinical Trial to Assess the Safety, Tolerability and Immunogenicity of MenABCWY in Healthy Infants</brief_title>
  <official_title>A PHASE 2b TRIAL TO ASSESS THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF MenABCWY IN HEALTHY INFANTS 2 AND 6 MONTHS OF AGE</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to describe the safety, tolerability, and immunogenicity of MenABCWY&#xD;
      in healthy infants 2 and 6 months of age.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 26, 2020</start_date>
  <completion_date type="Anticipated">June 4, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 4, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Care Provider, Investigator)</masking>
    <masking_description>Open label for Groups 1-5,7,8,10 and 11, no masking; Groups 13-14 is blinded.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>The percentage of participants achieving an hSBA titer ≥ LLOQ (Lower Limit of Quantitation) for each MenA, MenC, MenW, and MenY test strain - Groups 7 and 11 combined versus Groups 8 and 10 combined</measure>
    <time_frame>1 month after primary vaccination 2</time_frame>
    <description>To describe the immune response for MenA, MenC, MenW, and MenY induced by MenABCWY compared to the immune response induced by Nimenrix after 2 primary vaccinations.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The percentage of participants achieving an hSBA titer ≥ LLOQ for each MenA, MenC, MenW, and MenY test strain - Groups 7 and 11 combined versus Groups 8 and 10 combined</measure>
    <time_frame>1 month after the booster vaccination</time_frame>
    <description>To describe the immune response for MenA, MenC, MenW, and MenY induced by MenABCWY compared to the immune response induced by Nimenrix after a booster dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The percentage of participants achieving an hSBA titer ≥ LLOQ for each of the MenB test strains - Groups 7 and 11 combined versus Groups 8 and 10 combined</measure>
    <time_frame>1 month after primary vaccination 2</time_frame>
    <description>To describe the immune response for MenB induced by MenABCWY compared to the immune response induced by Bexsero after 2 primary vaccinations.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The percentage of participants achieving an hSBA titer ≥ LLOQ for each of the MenB test strains - Groups 7 and 11 combined versus Groups 8 and 10 combined</measure>
    <time_frame>1 month after the booster vaccination</time_frame>
    <description>To describe the immune response for MenB induced by MenABCWY compared to the immune response induced by Bexsero after a booster dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The percentage of participants achieving an hSBA titer ≥ LLOQ for each of the MenB test strains - Groups 3 and 4 combined versus Group 5</measure>
    <time_frame>1 month after primary vaccination 2</time_frame>
    <description>To describe the immune response for MenB induced by 60 µg and 120 µg of bivalent rLP2086 after 2 primary vaccinations.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The percentage of participants achieving an hSBA titer ≥ LLOQ for each of the MenB test strains - Groups 3 and 4 combined versus Group 5</measure>
    <time_frame>1 month after the booster vaccination</time_frame>
    <description>To describe the immune response for MenB induced by 60 µg and 120 µg of bivalent rLP2086 after a booster dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The percentage of participants reporting local reactions after each primary vaccination, by protocol-assigned paracetamol regimen and irrespective of paracetamol regimen, and after the booster vaccination - Groups 7 and 11 versus Groups 8 and 10</measure>
    <time_frame>With 7 days after each primary vaccination and after the booster vaccination</time_frame>
    <description>To describe the safety profile of MenABCWY after primary vaccinations with and without protocol-assigned paracetamol receipt, and after a booster dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The percentage of participants reporting systemic events after each primary vaccination, by protocol-assigned paracetamol regimen and irrespective of paracetamol regimen, and after the booster vaccination - Groups 7 and 11 versus Groups 8 and 10</measure>
    <time_frame>With 7 days after each primary vaccination and after the booster vaccination</time_frame>
    <description>To describe the safety profile of MenABCWY after primary vaccinations with and without protocol-assigned paracetamol receipt, and after a booster dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The percentage of participants reporting antipyretics use after each primary vaccination, by protocol-assigned paracetamol regimen and irrespective of paracetamol regimen, and after the booster vaccination - Groups 7 and 11 versus Groups 8 and 10</measure>
    <time_frame>With 7 days after each primary vaccination and after the booster vaccination</time_frame>
    <description>To describe the safety profile of MenABCWY after primary vaccinations with and without protocol-assigned paracetamol receipt, and after a booster dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The percentage of participants reporting at least 1 SAE (Serious Adverse Event) by protocol-assigned paracetamol regimen and irrespective of paracetamol regimen - Groups 7 and 11 versus Groups 8 and 10</measure>
    <time_frame>Within 30 days after each primary vaccination</time_frame>
    <description>To describe the safety profile of MenABCWY after primary vaccinations with and without protocol-assigned paracetamol receipt.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The percentage of participants reporting at least 1 SAE (Serious Adverse Event) by protocol-assigned paracetamol regimen and irrespective of paracetamol regimen - Groups 7 and 11 versus Groups 8 and 10</measure>
    <time_frame>Within 30 days after any primary vaccination</time_frame>
    <description>To describe the safety profile of MenABCWY after primary vaccinations with and without protocol-assigned paracetamol receipt.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The percentage of participants reporting at least 1 SAE by protocol-assigned paracetamol regimen and irrespective of paracetamol regimen - Groups 7 and 11 versus Groups 8 and 10</measure>
    <time_frame>From study entry through 1 month after primary vaccination 2</time_frame>
    <description>To describe the safety profile of MenABCWY after primary vaccinations with and without protocol-assigned paracetamol receipt.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The percentage of participants reporting at least 1 SAE by protocol-assigned paracetamol regimen and irrespective of paracetamol regimen - Groups 7 and 11 versus Groups 8 and 10</measure>
    <time_frame>From 1 month through 8 months after primary vaccination 2</time_frame>
    <description>To describe the safety profile of MenABCWY after primary vaccinations with and without protocol-assigned paracetamol receipt.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The percentage of participants reporting at least 1 SAE by protocol-assigned paracetamol regimen and irrespective of paracetamol regimen - Groups 7 and 11 versus Groups 8 and 10</measure>
    <time_frame>From study entry through 8 months after primary vaccination 2</time_frame>
    <description>To describe the safety profile of MenABCWY after primary vaccinations with and without protocol-assigned paracetamol receipt.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The percentage of participants reporting at least 1 MAE (Medically Attended Adverse Event) by protocol-assigned paracetamol regimen and irrespective of paracetamol regimen - Groups 7 and 11 versus Groups 8 and 10</measure>
    <time_frame>Within 30 days after each primary vaccination</time_frame>
    <description>To describe the safety profile of MenABCWY after primary vaccinations with and without protocol-assigned paracetamol receipt.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The percentage of participants reporting at least 1 MAE (Medically Attended Adverse Event) by protocol-assigned paracetamol regimen and irrespective of paracetamol regimen - Groups 7 and 11 versus Groups 8 and 10</measure>
    <time_frame>Within 30 days after any primary vaccination</time_frame>
    <description>To describe the safety profile of MenABCWY after primary vaccinations with and without protocol-assigned paracetamol receipt.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The percentage of participants reporting at least 1 MAE by protocol-assigned paracetamol regimen and irrespective of paracetamol regimen - Groups 7 and 11 versus Groups 8 and 10</measure>
    <time_frame>From study entry through 1 month after primary vaccination 2</time_frame>
    <description>To describe the safety profile of MenABCWY after primary vaccinations with and without protocol-assigned paracetamol receipt.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The percentage of participants reporting at least 1 MAE by protocol-assigned paracetamol regimen and irrespective of paracetamol regimen - Groups 7 and 11 versus Groups 8 and 10</measure>
    <time_frame>From 1 month through 8 months after primary vaccination 2</time_frame>
    <description>To describe the safety profile of MenABCWY after primary vaccinations with and without protocol-assigned paracetamol receipt.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The percentage of participants reporting at least 1 MAE by protocol-assigned paracetamol regimen and irrespective of paracetamol regimen - Groups 7 and 11 versus Groups 8 and 10</measure>
    <time_frame>From study entry through 8 months after primary vaccination 2</time_frame>
    <description>To describe the safety profile of MenABCWY after primary vaccinations with and without protocol-assigned paracetamol receipt.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The percentage of participants reporting at least 1 NDCMC (Newly Diagnosed Chronic Medical Condition) by protocol-assigned paracetamol regimen and irrespective of paracetamol regimen - Groups 7 and 11 versus Groups 8 and 10</measure>
    <time_frame>Within 30 days after each primary vaccination</time_frame>
    <description>To describe the safety profile of MenABCWY after primary vaccinations with and without protocol-assigned paracetamol receipt.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The percentage of participants reporting at least 1 NDCMC by protocol-assigned paracetamol regimen and irrespective of paracetamol regimen - Groups 7 and 11 versus Groups 8 and 10</measure>
    <time_frame>Within 30 days after any primary vaccination</time_frame>
    <description>To describe the safety profile of MenABCWY after primary vaccinations with and without protocol-assigned paracetamol receipt.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The percentage of participants reporting at least 1 NDCMC by protocol-assigned paracetamol regimen and irrespective of paracetamol regimen - Groups 7 and 11 versus Groups 8 and 10</measure>
    <time_frame>From study entry through 1 month after primary vaccination 2</time_frame>
    <description>To describe the safety profile of MenABCWY after primary vaccinations with and without protocol-assigned paracetamol receipt.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The percentage of participants reporting at least 1 NDCMC by protocol-assigned paracetamol regimen and irrespective of paracetamol regimen - Groups 7 and 11 versus Groups 8 and 10</measure>
    <time_frame>From 1 month through 8 months after primary vaccination 2</time_frame>
    <description>To describe the safety profile of MenABCWY after primary vaccinations with and without protocol-assigned paracetamol receipt.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The percentage of participants reporting at least 1 NDCMC by protocol-assigned paracetamol regimen and irrespective of paracetamol regimen - Groups 7 and 11 versus Groups 8 and 10</measure>
    <time_frame>From study entry through 8 months after primary vaccination 2</time_frame>
    <description>To describe the safety profile of MenABCWY after primary vaccinations with and without protocol-assigned paracetamol receipt.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The percentage of participants reporting at least 1 Adverse Event (AE) by protocol-assigned paracetamol regimen and irrespective of paracetamol regimen - Groups 7 and 11 versus Groups 8 and 10</measure>
    <time_frame>Within 30 days after each primary vaccination</time_frame>
    <description>To describe the safety profile of MenABCWY after primary vaccinations with and without protocol-assigned paracetamol receipt.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The percentage of participants reporting at least 1 Adverse Event (AE) by protocol-assigned paracetamol regimen and irrespective of paracetamol regimen - Groups 7 and 11 versus Groups 8 and 10</measure>
    <time_frame>Within 30 days after any primary vaccination</time_frame>
    <description>To describe the safety profile of MenABCWY after primary vaccinations with and without protocol-assigned paracetamol receipt.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The percentage of participants reporting at least 1 Adverse Event (AE) by protocol-assigned paracetamol regimen and irrespective of paracetamol regimen - Groups 7 and 11 versus Groups 8 and 10</measure>
    <time_frame>From study entry through 1 month after primary vaccination 2</time_frame>
    <description>To describe the safety profile of MenABCWY after primary vaccinations with and without protocol-assigned paracetamol receipt.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The percentage of participants reporting at least 1 immediate AE, by protocol-assigned paracetamol regimen and irrespective of paracetamol regimen - Groups 7 and 11 versus Groups 8 and 10</measure>
    <time_frame>Within 30 minutes after each primary vaccination and after the booster vaccination</time_frame>
    <description>To describe the safety profile of MenABCWY after primary vaccinations with and without protocol-assigned paracetamol receipt.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The percentage of participants reporting at least 1 SAE during the booster vaccination phase, regardless of protocol-assigned paracetamol receipt during primary vaccinations - Groups 7 and 11 versus Groups 8 and 10</measure>
    <time_frame>From the booster vaccination through 1 month after the booster vaccination</time_frame>
    <description>To describe the safety profile of MenABCWY after a booster dose, regardless of protocol-assigned paracetamol receipt during primary vaccinations.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The percentage of participants reporting at least 1 SAE during the booster follow-up phase, regardless of protocol-assigned paracetamol receipt during primary vaccinations - Groups 7 and 11 versus Groups 8 and 10</measure>
    <time_frame>From 1 month through 6 months after the booster vaccination</time_frame>
    <description>To describe the safety profile of MenABCWY after a booster dose, regardless of protocol-assigned paracetamol receipt after primary vaccinations.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The percentage of participants reporting at least 1 SAE throughout the booster stage, regardless of protocol-assigned paracetamol receipt during primary vaccinations - Groups 7 and 11 versus Groups 8 and 10</measure>
    <time_frame>From the booster vaccination through 6 months after the booster vaccination</time_frame>
    <description>To describe the safety profile of MenABCWY after a booster dose, regardless of protocol-assigned paracetamol receipt during primary vaccinations.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The percentage of participants reporting at least 1 MAE during the booster vaccination phase, regardless of protocol-assigned paracetamol receipt during primary vaccinations - Groups 7 and 11 versus Groups 8 and 10</measure>
    <time_frame>From the booster vaccination through 1 month after the booster vaccination</time_frame>
    <description>To describe the safety profile of MenABCWY after a booster dose, regardless of protocol-assigned paracetamol receipt during primary vaccinations.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The percentage of participants reporting at least 1 MAE during the booster follow-up phase, regardless of protocol-assigned paracetamol receipt during primary vaccinations - Groups 7 and 11 versus Groups 8 and 10</measure>
    <time_frame>From 1 month through 6 months after the booster vaccination</time_frame>
    <description>To describe the safety profile of MenABCWY after a booster dose, regardless of protocol-assigned paracetamol receipt during primary vaccinations.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The percentage of participants reporting at least 1 MAE throughout the booster stage, regardless of protocol-assigned paracetamol receipt during primary vaccinations - Groups 7 and 11 versus Groups 8 and 10</measure>
    <time_frame>From the booster vaccination through 6 months after the booster vaccination</time_frame>
    <description>To describe the safety profile of MenABCWY after a booster dose, regardless of protocol-assigned paracetamol receipt during primary vaccinations.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The percentage of participants reporting at least 1 NDCMC during the booster vaccination phase, regardless of protocol-assigned paracetamol receipt during primary vaccinations - Groups 7 and 11 versus Groups 8 and 10</measure>
    <time_frame>From the booster vaccination through 1 month after the booster vaccination</time_frame>
    <description>To describe the safety profile of MenABCWY after a booster dose, regardless of protocol-assigned paracetamol receipt during primary vaccinations.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The percentage of participants reporting at least 1 NDCMC during the booster follow-up phase, regardless of protocol-assigned paracetamol receipt during primary vaccinations - Groups 7 and 11 versus Groups 8 and 10</measure>
    <time_frame>From 1 month through 6 months after the booster vaccination</time_frame>
    <description>To describe the safety profile of MenABCWY after a booster dose, regardless of protocol-assigned paracetamol receipt during primary vaccinations.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The percentage of participants reporting at least 1 NDCMC throughout the booster stage, regardless of protocol-assigned paracetamol receipt during primary vaccinations - Groups 7 and 11 versus Groups 8 and 10</measure>
    <time_frame>From the booster vaccination through 6 months after the booster vaccination</time_frame>
    <description>To describe the safety profile of MenABCWY after a booster dose, regardless of protocol-assigned paracetamol receipt during primary vaccinations.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The percentage of participants reporting at least 1 AE during the booster vaccination phase, regardless of protocol-assigned paracetamol receipt during primary vaccinations - Groups 7 and 11 versus Groups 8 and 10</measure>
    <time_frame>From the booster vaccination through 1 month after the booster vaccination</time_frame>
    <description>To describe the safety profile of MenABCWY after a booster dose, regardless of protocol-assigned paracetamol receipt during primary vaccinations.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The percentage of participants achieving an hSBA titer ≥ LLOQ (Lower Limit of Quantitation) for each MenA, MenC, MenW, and MenY test strain - Group 13 versus Group 14</measure>
    <time_frame>1 month after primary vaccination 2</time_frame>
    <description>To describe the immune response for MenA, MenC, MenW, and MenY induced by MenABCWY compared to the immune response induced by Nimenrix after 2 primary vaccinations.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The percentage of participants achieving an hSBA titer ≥ LLOQ (Lower Limit of Quantitation) for each MenA, MenC, MenW, and MenY test strain - Group 13 versus Group 14</measure>
    <time_frame>1 month after the booster vaccination</time_frame>
    <description>To describe the immune response for MenA, MenC, MenW, and MenY induced by MenABCWY compared to the immune response induced by Nimenrix after a booster dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The percentage of participants achieving an hSBA titer ≥ LLOQ for each of the MenB test strains - Group 13 versus Group 14</measure>
    <time_frame>1 month after primary vaccination 2</time_frame>
    <description>To describe the immune response for MenB induced by MenABCWY compared to the immune response induced by Bexsero after 2 primary vaccinations.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The percentage of participants achieving an hSBA titer ≥ LLOQ for each of the MenB test strains - Group 13 versus Group 14</measure>
    <time_frame>1 month after the booster vaccination</time_frame>
    <description>To describe the immune response for MenB induced by MenABCWY compared to the immune response induced by Bexsero after a booster dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>hSBA GMTs for each of the MenA, MenC, MenW, and MenY test strains - Group 13 versus Group 14</measure>
    <time_frame>1 month after primary vaccination 2</time_frame>
    <description>To describe the immune response for MenA, MenC, MenW, and MenY induced by MenABCWY compared to the immune response induced by Nimenrix after 2 primary vaccinations.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>hSBA GMTs for each of the MenB test strains - Group 13 versus Group 14</measure>
    <time_frame>1 month after primary vaccination 2</time_frame>
    <description>To describe the immune response for each of MenB strains induced by MenABCWY compared to the immune response induced by Bexsero after 2 primary vaccinations.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>hSBA GMTs for each of the MenA, MenC, MenW, and MenY test strains - Group 13 versus Group 14</measure>
    <time_frame>1 month after the booster vaccination</time_frame>
    <description>To describe the immune response for MenA, MenC, MenW, and MenY induced by MenABCWY compared to the immune response induced by Nimenrix after the booster vaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>hSBA GMTs for each of the MenB test strains - Group 13 versus Group 14</measure>
    <time_frame>1 month after the booster vaccination</time_frame>
    <description>To describe the immune response for MenB induced by MenABCWY compared to the immune response induced by Bexsero after the booster vaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The percentage of participants reporting local reactions after each primary vaccination, by protocol-assigned paracetamol regimen, and after the booster vaccination - Group 13 versus Group 14</measure>
    <time_frame>With 7 days after each primary vaccination and after the booster vaccination</time_frame>
    <description>To describe the safety profile of MenABCWY after primary vaccinations, by protocol-assigned paracetamol receipt, and after a booster dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The percentage of participants reporting systemic events after each primary vaccination, by protocol-assigned paracetamol regimen, and after the booster vaccination - Group 13 versus Group 14</measure>
    <time_frame>With 7 days after each primary vaccination and after the booster vaccination</time_frame>
    <description>To describe the safety profile of MenABCWY after primary vaccinations, by protocol-assigned paracetamol receipt, and after a booster dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The percentage of participants reporting use of antipyretic medication after each primary vaccination, by protocol-assigned paracetamol regimen, and after the booster vaccination - Group 13 versus Group 14</measure>
    <time_frame>With 7 days after each primary vaccination and after the booster vaccination</time_frame>
    <description>To describe the safety profile of MenABCWY after primary vaccinations, by protocol-assigned paracetamol regimen receipt, and after a booster dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The percentage of participants reporting at least 1 SAE within 30 days after each primary vaccination, by protocol-assigned paracetamol regimen- Group 13 versus Group 14</measure>
    <time_frame>Within 30 days after each primary vaccination</time_frame>
    <description>To describe the safety profile of MenABCWY after primary vaccinations by protocol-assigned paracetamol regimen receipt.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The percentage of participants reporting at least 1 SAE within 30 days after any primary vaccination, by protocol-assigned paracetamol regimen - Group 13 versus Group 14</measure>
    <time_frame>Within 30 days after any primary vaccination</time_frame>
    <description>To describe the safety profile of MenABCWY after primary vaccinations by protocol-assigned paracetamol receipt.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The percentage of participants reporting at least 1 SAE from study entry through 1 month after primary vaccination 2, by protocol-assigned paracetamol regimen - Group 13 versus Group 14</measure>
    <time_frame>From study entry through 1 month after primary vaccination 2</time_frame>
    <description>To describe the safety profile of MenABCWY after primary vaccinations by protocol-assigned paracetamol receipt.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The percentage of participants reporting at least 1 SAE from 1 month through 8 months after primary vaccination 2, by protocol-assigned paracetamol regimen - Group 13 versus Group 14</measure>
    <time_frame>From 1 month through 8 months after primary vaccination 2</time_frame>
    <description>To describe the safety profile of MenABCWY after primary vaccinations by protocol-assigned paracetamol receipt.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The percentage of participants reporting at least 1 SAE from study entry through 8 months after primary vaccination 2, by protocol-assigned paracetamol regimen - Group 13 versus Group 14</measure>
    <time_frame>From study entry through 8 months after primary vaccination 2</time_frame>
    <description>To describe the safety profile of MenABCWY after primary vaccinations by protocol-assigned paracetamol receipt.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The percentage of participants reporting at least 1 MAE within 30 days after each primary vaccination, by protocol-assigned paracetamol regimen - Group 13 versus Group 14</measure>
    <time_frame>Within 30 days after each primary vaccination</time_frame>
    <description>To describe the safety profile of MenABCWY after primary vaccinations by protocol-assigned paracetamol receipt.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The percentage of participants reporting at least 1 MAE within 30 days after any primary vaccination, by protocol-assigned paracetamol regimen - Group 13 versus Group 14</measure>
    <time_frame>Within 30 days after any primary vaccination</time_frame>
    <description>To describe the safety profile of MenABCWY after primary vaccinations by protocol-assigned paracetamol receipt.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The percentage of participants reporting at least 1 MAE from study entry through 1 month after primary vaccination 2, by protocol-assigned paracetamol regimen - Group 13 versus Group 14</measure>
    <time_frame>From study entry through 1 month after primary vaccination 2</time_frame>
    <description>To describe the safety profile of MenABCWY after primary vaccinations by protocol-assigned paracetamol receipt.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The percentage of participants reporting at least 1 MAE from 1 month through 8 months after primary vaccination 2, by protocol-assigned paracetamol regimen - Group 13 versus Group 14</measure>
    <time_frame>From 1 month through 8 months after primary vaccination 2</time_frame>
    <description>To describe the safety profile of MenABCWY after primary vaccinations by protocol-assigned paracetamol receipt.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The percentage of participants reporting at least 1 MAE from study entry through 8 months after primary vaccination 2, by protocol-assigned paracetamol regimen - Group 13 versus Group 14</measure>
    <time_frame>From study entry through 8 months after primary vaccination 2</time_frame>
    <description>To describe the safety profile of MenABCWY after primary vaccinations by protocol-assigned paracetamol receipt.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The percentage of participants reporting at least 1 NDCMC within 30 days after each primary vaccination, by protocol-assigned paracetamol regimen - Group 13 versus Group 14</measure>
    <time_frame>Within 30 days after each primary vaccination</time_frame>
    <description>To describe the safety profile of MenABCWY after primary vaccinations by protocol-assigned paracetamol receipt.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The percentage of participants reporting at least 1 NDCMC within 30 days after any primary vaccination, by protocol-assigned paracetamol regimen - Group 13 versus Group 14</measure>
    <time_frame>Within 30 days after any primary vaccination</time_frame>
    <description>To describe the safety profile of MenABCWY after primary vaccinations by protocol-assigned paracetamol receipt.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The percentage of participants reporting at least 1 NDCMC from study entry through 1 month after primary vaccination 2, by protocol-assigned paracetamol regimen - Group 13 versus Group 14</measure>
    <time_frame>From study entry through 1 month after primary vaccination 2</time_frame>
    <description>To describe the safety profile of MenABCWY after primary vaccinations by protocol-assigned paracetamol receipt.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The percentage of participants reporting at least 1 NDCMC from 1 month through 8 months after primary vaccination 2, by protocol-assigned paracetamol regimen - Group 13 versus Group 14</measure>
    <time_frame>From 1 month through 8 months after primary vaccination 2</time_frame>
    <description>To describe the safety profile of MenABCWY after primary vaccinations by protocol-assigned paracetamol receipt.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The percentage of participants reporting at least 1 NDCMC from study entry through 8 months after primary vaccination 2, by protocol-assigned paracetamol regimen - Group 13 versus Group 14</measure>
    <time_frame>From study entry through 8 months after primary vaccination 2</time_frame>
    <description>To describe the safety profile of MenABCWY after primary vaccinations by protocol-assigned paracetamol receipt.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The percentage of participants reporting at least 1 AE within 30 days after each primary vaccination, by protocol-assigned paracetamol regimen - Group 13 versus Group 14</measure>
    <time_frame>Within 30 days after each primary vaccination</time_frame>
    <description>To describe the safety profile of MenABCWY after primary vaccinations by protocol-assigned paracetamol receipt.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The percentage of participants reporting at least 1 AE within 30 days after any primary vaccination, by protocol-assigned paracetamol regimen - Group 13 versus Group 14</measure>
    <time_frame>Within 30 days after any primary vaccination</time_frame>
    <description>To describe the safety profile of MenABCWY after primary vaccinations by protocol-assigned paracetamol receipt.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The percentage of participants reporting at least 1 AE from study entry through 1 month after primary vaccination 2, by protocol-assigned paracetamol regimen - Group 13 versus Group 14</measure>
    <time_frame>From study entry through 1 month after primary vaccination 2</time_frame>
    <description>To describe the safety profile of MenABCWY after primary vaccinations by protocol-assigned paracetamol receipt.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The percentage of participants reporting at least 1 immediate AE within 30 minutes after each primary vaccination, by protocol-assigned paracetamol regimen, and after the booster vaccination - Group 13 versus Group 14</measure>
    <time_frame>Within 30 minutes after each primary vaccination and after the booster vaccination</time_frame>
    <description>To describe the safety profile of MenABCWY after primary vaccinations by protocol-assigned paracetamol receipt.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The percentage of participants reporting at least 1 SAE during the booster vaccination phase, regardless of protocol-assigned paracetamol receipt - Group 13 versus Group 14</measure>
    <time_frame>From the booster vaccination through 1 month after the booster vaccination</time_frame>
    <description>To describe the safety profile of MenABCWY after a booster dose, regardless of protocol-assigned paracetamol regimen receipt during primary vaccinations.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The percentage of participants reporting at least 1 SAE during the booster follow-up phase, regardless of protocol-assigned paracetamol receipt - Group 13 versus Group 14</measure>
    <time_frame>From 1 month through 6 months after the booster vaccination</time_frame>
    <description>To describe the safety profile of MenABCWY after a booster dose, regardless of protocol-assigned paracetamol receipt during primary vaccinations.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The percentage of participants reporting at least 1 SAE throughout the booster stage, regardless of protocol-assigned paracetamol receipt - Group 13 versus Group 14</measure>
    <time_frame>From the booster vaccination through 6 months after the booster vaccination</time_frame>
    <description>To describe the safety profile of MenABCWY after a booster dose, regardless of protocol-assigned paracetamol receipt during primary vaccinations.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The percentage of participants reporting at least 1 MAE during the booster vaccination phase, regardless of protocol-assigned paracetamol receipt - Group 13 versus Group 14</measure>
    <time_frame>From the booster vaccination through 1 month after the booster vaccination</time_frame>
    <description>To describe the safety profile of MenABCWY after a booster dose, regardless of protocol-assigned paracetamol receipt during primary vaccinations.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The percentage of participants reporting at least 1 MAE during the booster follow-up phase, regardless of protocol-assigned paracetamol receipt - Group 13 versus Group 14</measure>
    <time_frame>From 1 month through 6 months after the booster vaccination</time_frame>
    <description>To describe the safety profile of MenABCWY after a booster dose, regardless of protocol-assigned paracetamol receipt during primary vaccinations.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The percentage of participants reporting at least 1 MAE throughout the booster stage, regardless of protocol-assigned paracetamol receipt - Group 13 versus Group 14</measure>
    <time_frame>From the booster vaccination through 6 months after the booster vaccination</time_frame>
    <description>To describe the safety profile of MenABCWY after a booster dose, regardless of protocol-assigned paracetamol receipt during primary vaccinations.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The percentage of participants reporting at least 1 NDCMC during the booster vaccination phase, regardless of protocol-assigned paracetamol receipt - Group 13 versus Group 14</measure>
    <time_frame>From the booster vaccination through 1 month after the booster vaccination</time_frame>
    <description>To describe the safety profile of MenABCWY after a booster dose, regardless of protocol-assigned paracetamol receipt during primary vaccinations.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The percentage of participants reporting at least 1 NDCMC during the booster follow-up phase, regardless of protocol-assigned paracetamol receipt - Group 13 versus Group 14</measure>
    <time_frame>From 1 month through 6 months after the booster vaccination</time_frame>
    <description>To describe the safety profile of MenABCWY after a booster dose, regardless of protocol-assigned paracetamol receipt during primary vaccinations.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The percentage of participants reporting at least 1 NDCMC throughout the booster stage, regardless of protocol-assigned paracetamol receipt - Group 13 versus Group 14</measure>
    <time_frame>From the booster vaccination through 6 months after the booster vaccination</time_frame>
    <description>To describe the safety profile of MenABCWY after a booster dose, regardless of protocol-assigned paracetamol receipt during primary vaccinations.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The percentage of participants reporting at least 1 AE during the booster vaccination phase, regardless of protocol-assigned paracetamol receipt - Group 13 versus Group 14</measure>
    <time_frame>From the booster vaccination through 1 month after the booster vaccination</time_frame>
    <description>To describe the safety profile of MenABCWY after a booster dose, regardless of protocol-assigned paracetamol receipt during primary vaccinations.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>hSBA GMTs (Geometric Mean Titer) for each of the MenB test strains - Groups 3 and 4 combined versus Group 5</measure>
    <time_frame>1 month after primary vaccination 2</time_frame>
    <description>To further describe the immune response for MenB induced by 60 µg and 120 µg of bivalent rLP2086 after 2 primary vaccinations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hSBA GMTs for each of the MenB test strains - Groups 3 and 4 combined versus Group 5</measure>
    <time_frame>1 month after the booster vaccination</time_frame>
    <description>To further describe the immune response for MenB induced by 60 µg and 120 µg of bivalent rLP2086 after the booster vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of participants reporting local reactions after each primary vaccination, by protocol-assigned paracetamol regimen and irrespective of protocol-assigned paracetamol receipt, and after the booster vaccination - Group 3, Group 4 and Group 5</measure>
    <time_frame>Within 7 days after each primary vaccination and after the booster vaccination</time_frame>
    <description>To describe the safety profile of 60 µg and 120 µg of bivalent rLP2086 after primary vaccinations, with and without protocol-assigned paracetamol receipt, and after a booster dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of participants reporting systemic events after each primary vaccination, by protocol-assigned paracetamol regimen and irrespective of protocol-assigned paracetamol receipt, and after the booster vaccination - Group 3, Group 4 and Group 5</measure>
    <time_frame>Within 7 days after each primary vaccination and after the booster vaccination</time_frame>
    <description>To describe the safety profile of 60 µg and 120 µg of bivalent rLP2086 after primary vaccinations, with and without protocol-assigned paracetamol receipt, and after a booster dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of participants reporting antipyretics use after each primary vaccination, by protocol-assigned paracetamol regimen and irrespective of paracetamol regimen, and after the booster vaccination - Group 3, Group 4 and Group 5</measure>
    <time_frame>Within 7 days after each primary vaccination and after the booster vaccination</time_frame>
    <description>To describe the safety profile of 60 µg and 120 µg of bivalent rLP2086 after primary vaccinations, with and without protocol-assigned paracetamol receipt, and after a booster dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of participants reporting at least 1 SAE within 30 days after each primary vaccination, by protocol-assigned paracetamol regimen and irrespective of protocol-assigned paracetamol receipt - Group 3, Group 4 and Group 5</measure>
    <time_frame>Within 30 days after each primary vaccination</time_frame>
    <description>To describe the safety profile of 60 µg and 120 µg of bivalent rLP2086 after primary vaccinations, with and without protocol-assigned paracetamol receipt.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of participants reporting at least 1 SAE within 30 days after any primary vaccination, by protocol-assigned paracetamol regimen and irrespective of protocol-assigned paracetamol receipt - Group 3, Group 4 and Group 5</measure>
    <time_frame>Within 30 days after any primary vaccination</time_frame>
    <description>To describe the safety profile of 60 µg and 120 µg of bivalent rLP2086 after primary vaccinations, with and without protocol-assigned paracetamol receipt.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of participants reporting at least 1 SAE during the primary series vaccination phase, by protocol-assigned paracetamol regimen and irrespective of protocol-assigned paracetamol receipt - Group 3, Group 4 and Group 5</measure>
    <time_frame>From study entry through 1 month after primary vaccination 2</time_frame>
    <description>To describe the safety profile of 60 µg and 120 µg of bivalent rLP2086 after primary vaccinations, with and without protocol-assigned paracetamol receipt.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of participants reporting at least 1 SAE during the primary series follow-up phase, by protocol-assigned paracetamol regimen and irrespective of protocol-assigned paracetamol receipt - Group 3, Group 4 and Group 5</measure>
    <time_frame>From 1 month through 8 months after primary vaccination 2</time_frame>
    <description>To describe the safety profile of 60 µg and 120 µg of bivalent rLP2086 after primary vaccinations, with and without protocol-assigned paracetamol receipt.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of participants reporting at least 1 SAE throughout the primary series stage, by protocol-assigned paracetamol regimen and irrespective of protocol-assigned paracetamol receipt - Group 3, Group 4 and Group 5</measure>
    <time_frame>From study entry through 8 months after primary vaccination 2</time_frame>
    <description>To describe the safety profile of 60 µg and 120 µg of bivalent rLP2086 after primary vaccinations, with and without protocol-assigned paracetamol receipt.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of participants reporting at least 1 MAE within 30 days after each primary vaccination, by protocol-assigned paracetamol regimen and irrespective of protocol-assigned paracetamol receipt - Group 3, Group 4 and Group 5</measure>
    <time_frame>Within 30 days after each primary vaccination</time_frame>
    <description>To describe the safety profile of 60 µg and 120 µg of bivalent rLP2086 after primary vaccinations, with and without protocol-assigned paracetamol receipt.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of participants reporting at least 1 MAE within 30 days after any primary vaccination, by protocol-assigned paracetamol regimen and irrespective of protocol-assigned paracetamol receipt - Group 3, Group 4 and Group 5</measure>
    <time_frame>Within 30 days after any primary vaccination</time_frame>
    <description>To describe the safety profile of 60 µg and 120 µg of bivalent rLP2086 after primary vaccinations, with and without protocol-assigned paracetamol receipt.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of participants reporting at least 1 MAE during the primary series vaccination phase, by protocol-assigned paracetamol regimen and irrespective of protocol-assigned paracetamol receipt - Group 3, Group 4 and Group 5</measure>
    <time_frame>From study entry through 1 month after primary vaccination 2</time_frame>
    <description>To describe the safety profile of 60 µg and 120 µg of bivalent rLP2086 after primary vaccinations, with and without protocol-assigned paracetamol receipt.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of participants reporting at least 1 MAE during the primary series follow-up phase, by protocol-assigned paracetamol regimen and irrespective of protocol-assigned paracetamol receipt - Group 3, Group 4 and Group 5</measure>
    <time_frame>From 1 month through 8 months after primary vaccination 2</time_frame>
    <description>To describe the safety profile of 60 µg and 120 µg of bivalent rLP2086 after primary vaccinations, with and without protocol-assigned paracetamol receipt.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of participants reporting at least 1 MAE throughout the primary series stage, by protocol-assigned paracetamol regimen and irrespective of protocol-assigned paracetamol receipt - Group 3, Group 4 and Group 5</measure>
    <time_frame>From study entry through 8 months after primary vaccination 2</time_frame>
    <description>To describe the safety profile of 60 µg and 120 µg of bivalent rLP2086 after primary vaccinations, with and without protocol-assigned paracetamol receipt.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of participants reporting at least 1 NDCMC within 30 days after each primary vaccination, by protocol-assigned paracetamol regimen and irrespective of protocol-assigned paracetamol receipt - Group 3, Group 4 and Group 5</measure>
    <time_frame>Within 30 days after each primary vaccination</time_frame>
    <description>To describe the safety profile of 60 µg and 120 µg of bivalent rLP2086 after primary vaccinations, with and without protocol-assigned paracetamol receipt.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of participants reporting at least 1 NDCMC within 30 days after any primary vaccination, by protocol-assigned paracetamol regimen and irrespective of protocol-assigned paracetamol receipt - Group 3, Group 4 and Group 5</measure>
    <time_frame>Within 30 days after any primary vaccination</time_frame>
    <description>To describe the safety profile of 60 µg and 120 µg of bivalent rLP2086 after primary vaccinations, with and without protocol-assigned paracetamol receipt.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of participants reporting at least 1 NDCMC during the primary series vaccination phase, by protocol-assigned paracetamol regimen and irrespective of protocol-assigned paracetamol receipt - Group 3, Group 4 and Group 5</measure>
    <time_frame>From study entry through 1 month after primary vaccination 2</time_frame>
    <description>To describe the safety profile of 60 µg and 120 µg of bivalent rLP2086 after primary vaccinations, with and without protocol-assigned paracetamol receipt.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of participants reporting at least 1 NDCMC during the primary series vaccination phase, by protocol-assigned paracetamol regimen and irrespective of protocol-assigned paracetamol receipt - Group 3, Group 4 and Group 5</measure>
    <time_frame>From 1 month through 8 months after primary vaccination 2</time_frame>
    <description>To describe the safety profile of 60 µg and 120 µg of bivalent rLP2086 after primary vaccinations, with and without protocol-assigned paracetamol receipt.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of participants reporting at least 1 NDCMC throughout the primary series stage, by protocol-assigned paracetamol regimen and irrespective of protocol-assigned paracetamol receipt - Group 3, Group 4 and Group 5</measure>
    <time_frame>From study entry through 8 months after primary vaccination 2</time_frame>
    <description>To describe the safety profile of 60 µg and 120 µg of bivalent rLP2086 after primary vaccinations, with and without protocol-assigned paracetamol receipt.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of participants reporting at least 1 AE within 30 days after each primary vaccination, by protocol-assigned paracetamol regimen and irrespective of protocol-assigned paracetamol receipt - Group 3, Group 4 and Group 5</measure>
    <time_frame>Within 30 days after each primary vaccination</time_frame>
    <description>To describe the safety profile of 60 µg and 120 µg of bivalent rLP2086 after primary vaccinations, with and without protocol-assigned paracetamol receipt.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of participants reporting at least 1 AE within 30 days after any primary vaccination, by protocol-assigned paracetamol regimen and irrespective of protocol-assigned paracetamol receipt - Group 3, Group 4 and Group 5</measure>
    <time_frame>Within 30 days after any primary vaccination</time_frame>
    <description>To describe the safety profile of 60 µg and 120 µg of bivalent rLP2086 after primary vaccinations, with and without protocol-assigned paracetamol receipt.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of participants reporting at least 1 AE during the primary series vaccination phase, by protocol-assigned paracetamol regimen and irrespective of protocol-assigned paracetamol receipt - Group 3, Group 4 and Group 5</measure>
    <time_frame>From study entry through 1 month after primary vaccination 2</time_frame>
    <description>To describe the safety profile of 60 µg and 120 µg of bivalent rLP2086 after primary vaccinations, with and without protocol-assigned paracetamol receipt.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of participants reporting at least 1 immediate AE, by protocol-assigned paracetamol regimen and irrespective of paracetamol regimen, and after the booster vaccination - Group 3, Group 4 and Group 5</measure>
    <time_frame>Within 30 minutes of each primary vaccination and after the booster vaccination</time_frame>
    <description>To describe the safety profile of 60 µg and 120 µg of bivalent rLP2086 after primary vaccinations, with and without protocol-assigned paracetamol receipt during primary vaccinations, and after a booster dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of participants reporting at least 1 SAE during the booster vaccination phase, regardless of protocol-assigned paracetamol receipt - Group 3, Group 4 and Group 5</measure>
    <time_frame>From the booster vaccination through 1 month after the booster vaccination</time_frame>
    <description>To describe the safety profile of 60 µg and 120 µg of bivalent rLP2086 after a booster dose regardless of protocol-assigned paracetamol receipt during primary vaccinations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of participants reporting at least 1 SAE during the booster follow-up phase, regardless of protocol-assigned paracetamol receipt - Group 3, Group 4 and Group 5</measure>
    <time_frame>From 1 month through 6 months after the booster vaccination</time_frame>
    <description>To describe the safety profile of 60 µg and 120 µg of bivalent rLP2086 after a booster dose regardless of protocol-assigned paracetamol receipt during primary vaccinations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of participants reporting at least 1 SAE throughout the booster stage, regardless of protocol-assigned paracetamol receipt - Group 3, Group 4 and Group 5</measure>
    <time_frame>From the booster vaccination through 6 months after the booster vaccination</time_frame>
    <description>To describe the safety profile of 60 µg and 120 µg of bivalent rLP2086 after a booster dose regardless of protocol-assigned paracetamol receipt during primary vaccinations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of participants reporting at least 1 MAE during the booster vaccination phase, regardless of protocol-assigned paracetamol receipt - Group 3, Group 4 and Group 5</measure>
    <time_frame>From the booster vaccination through 1 month after the booster vaccination</time_frame>
    <description>To describe the safety profile of 60 µg and 120 µg of bivalent rLP2086 after a booster dose regardless of protocol-assigned paracetamol receipt during primary vaccinations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of participants reporting at least 1 MAE during the booster follow-up phase, regardless of protocol-assigned paracetamol receipt - Group 3, Group 4 and Group 5</measure>
    <time_frame>From 1 month through 6 months after the booster vaccination</time_frame>
    <description>To describe the safety profile of 60 µg and 120 µg of bivalent rLP2086 after a booster dose regardless of protocol-assigned paracetamol receipt during primary vaccinations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of participants reporting at least 1 MAE throughout the booster stage, regardless of protocol-assigned paracetamol receipt - Group 3, Group 4 and Group 5</measure>
    <time_frame>From the booster vaccination through 6 months after the booster vaccination</time_frame>
    <description>To describe the safety profile of 60 µg and 120 µg of bivalent rLP2086 after a booster dose regardless of protocol-assigned paracetamol receipt during primary vaccinations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of participants reporting at least 1 NDCMC during the booster vaccination phase, regardless of protocol-assigned paracetamol receipt - Group 3, Group 4 and Group 5</measure>
    <time_frame>From the booster vaccination through 1 month after the booster vaccination</time_frame>
    <description>To describe the safety profile of 60 µg and 120 µg of bivalent rLP2086 after a booster dose regardless of protocol-assigned paracetamol receipt during primary vaccinations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of participants reporting at least 1 NDCMC during the booster follow-up phase, regardless of protocol-assigned paracetamol receipt - Group 3, Group 4 and Group 5</measure>
    <time_frame>From 1 month through 6 months after the booster vaccination</time_frame>
    <description>To describe the safety profile of 60 µg and 120 µg of bivalent rLP2086 after a booster dose regardless of protocol-assigned paracetamol receipt during primary vaccinations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of participants reporting at least 1 NDCMC throughout the booster stage, regardless of protocol-assigned paracetamol receipt - Group 3, Group 4 and Group 5</measure>
    <time_frame>From the booster vaccination through 6 months after the booster vaccination</time_frame>
    <description>To describe the safety profile of 60 µg and 120 µg of bivalent rLP2086 after a booster dose regardless of protocol-assigned paracetamol receipt during primary vaccinations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of participants reporting at least 1 AE during the booster vaccination phase, regardless of protocol-assigned paracetamol receipt - Group 3, Group 4 and Group 5</measure>
    <time_frame>From the booster vaccination through 1 month after the booster vaccination</time_frame>
    <description>To describe the safety profile of 60 µg and 120 µg of bivalent rLP2086 after a booster dose regardless of protocol-assigned paracetamol receipt during primary vaccinations.</description>
  </secondary_outcome>
  <number_of_arms>11</number_of_arms>
  <enrollment type="Anticipated">1272</enrollment>
  <condition>Meningococcal Vaccine</condition>
  <arm_group>
    <arm_group_label>MenABCWY with PLP - 6 months of age</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 1 - Participants 6 months of age vaccinated with MenABCWY on a 2+1 (2 primary vaccinations and a booster dose) schedule, and given Prophylactic Liquid Paracetamol (PLP) during primary vaccinations.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MenABCWY - 6 months of age</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 2 - Participants 6 months of age vaccinated with MenABCWY on a 2+1 schedule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bivalent rLP2086 (60-µg Dose) and Nimerix, with PLP or SLP - 2 months of age</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 3 - Participants 2 months of age vaccinated with Bivalent rLP2086 (60-µg Dose) and Nimenrix on a 2+1 schedule, with PLP or Scheduled Liquid Paracetamol (SLP) during primary vaccinations.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bivalent rLP2086 (60-µg Dose) and Nimenrix - 2 months of age</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 4 - Participants 2 months of age vaccinated with Bivalent rLP2086 (60-mcg Dose) and Nimenrix on a 2+1 schedule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bivalent rLP2086 (120-µg Dose) and Nimenrix, with PLP - 2 months of age</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 5 - Participants 2 months of age vaccinated with Bivalent rLP2086 (120-µg Dose) and Nimenrix on a 2+1 schedule, and given PLP during primary vaccinations.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MenABCWY with SLP - 2 months of age</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 7 - Participants 2 months of age vaccinated with MenABCWY on a 2+1 schedule, and given SLP during primary vaccinations.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bexsero and Nimenrix with PLP - 2 months of age</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 8 - Participants 2 months of age vaccinated with Bexsero and Nimenrix on a 2+1 schedule, and given PLP during primary vaccinations</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bexsero and Nimenrix - 2 months of age</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 10 - Participants 2 months of age vaccinated with Bexsero and Nimenrix on a 2+1 schedule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MenABCWY with TLP - 2 months of age</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 11 - Participants 2 months of age vaccinated with MenABCWY on a 2+1 schedule, with Therapeutic Liquid Paracetamol (TLP) during primary vaccinations.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Blinded: MenABCWY and placebo with SLP or TLP - 2 months of age</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 13 - Participants 2 months of age vaccinated with MenABCWY and placebo on a 2+1 schedule, with a determined ratio of participants given SLP or TLP during primary vaccinations.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Blinded: Bexsero and Nimenrix with PLP or TLP - 2 months of age</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 14 - Participants 2 months of age vaccinated with Bexsero and Nimenrix on a 2+1 schedule with a determined ratio of participants given PLP or TLP during primary vaccinations.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MenABCWY</intervention_name>
    <description>Neisseria meningitis groups A, B, C W, and Y vaccine</description>
    <arm_group_label>Blinded: MenABCWY and placebo with SLP or TLP - 2 months of age</arm_group_label>
    <arm_group_label>MenABCWY - 6 months of age</arm_group_label>
    <arm_group_label>MenABCWY with PLP - 6 months of age</arm_group_label>
    <arm_group_label>MenABCWY with SLP - 2 months of age</arm_group_label>
    <arm_group_label>MenABCWY with TLP - 2 months of age</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Bivalent rLP2086 (60-µg Dose)</intervention_name>
    <description>Trumenba (half dose) - Meningococcal Group B vaccine</description>
    <arm_group_label>Bivalent rLP2086 (60-µg Dose) and Nimenrix - 2 months of age</arm_group_label>
    <arm_group_label>Bivalent rLP2086 (60-µg Dose) and Nimerix, with PLP or SLP - 2 months of age</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Bivalent rLP2086 (120-µg Dose)</intervention_name>
    <description>Trumenba - Meningococcal Group B vaccine</description>
    <arm_group_label>Bivalent rLP2086 (120-µg Dose) and Nimenrix, with PLP - 2 months of age</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Bexsero</intervention_name>
    <description>Bexsero - Meningococcal Group B vaccine</description>
    <arm_group_label>Bexsero and Nimenrix - 2 months of age</arm_group_label>
    <arm_group_label>Bexsero and Nimenrix with PLP - 2 months of age</arm_group_label>
    <arm_group_label>Blinded: Bexsero and Nimenrix with PLP or TLP - 2 months of age</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prophylactic Liquid Paracetamol (PLP)</intervention_name>
    <description>PLP administration during primary vaccinations 1 and 2</description>
    <arm_group_label>Bexsero and Nimenrix with PLP - 2 months of age</arm_group_label>
    <arm_group_label>Bivalent rLP2086 (120-µg Dose) and Nimenrix, with PLP - 2 months of age</arm_group_label>
    <arm_group_label>Bivalent rLP2086 (60-µg Dose) and Nimerix, with PLP or SLP - 2 months of age</arm_group_label>
    <arm_group_label>Blinded: Bexsero and Nimenrix with PLP or TLP - 2 months of age</arm_group_label>
    <arm_group_label>MenABCWY with PLP - 6 months of age</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Nimenrix</intervention_name>
    <description>Nimenrix - Meningococcal Group A, C, W and Y vaccine</description>
    <arm_group_label>Bexsero and Nimenrix - 2 months of age</arm_group_label>
    <arm_group_label>Bexsero and Nimenrix with PLP - 2 months of age</arm_group_label>
    <arm_group_label>Bivalent rLP2086 (120-µg Dose) and Nimenrix, with PLP - 2 months of age</arm_group_label>
    <arm_group_label>Bivalent rLP2086 (60-µg Dose) and Nimenrix - 2 months of age</arm_group_label>
    <arm_group_label>Bivalent rLP2086 (60-µg Dose) and Nimerix, with PLP or SLP - 2 months of age</arm_group_label>
    <arm_group_label>Blinded: Bexsero and Nimenrix with PLP or TLP - 2 months of age</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Normal Saline</description>
    <arm_group_label>Blinded: MenABCWY and placebo with SLP or TLP - 2 months of age</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Scheduled Liquid Paracetamol (SLP)</intervention_name>
    <description>SLP administration after primary vaccinations 1 and 2.</description>
    <arm_group_label>Bivalent rLP2086 (60-µg Dose) and Nimerix, with PLP or SLP - 2 months of age</arm_group_label>
    <arm_group_label>Blinded: MenABCWY and placebo with SLP or TLP - 2 months of age</arm_group_label>
    <arm_group_label>MenABCWY with SLP - 2 months of age</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Therapeutic Liquid Paracetamol (TLP)</intervention_name>
    <description>TLP administration after primary vaccinations 1 and 2</description>
    <arm_group_label>Blinded: Bexsero and Nimenrix with PLP or TLP - 2 months of age</arm_group_label>
    <arm_group_label>Blinded: MenABCWY and placebo with SLP or TLP - 2 months of age</arm_group_label>
    <arm_group_label>MenABCWY with TLP - 2 months of age</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male and female participants, 2 months of age (≥60 to ≤98 days) or 6 months of age&#xD;
             (≥150 to ≤210 days) at the time of randomization.&#xD;
&#xD;
          2. Participant's parent(s)/legal guardian who are willing and able to comply with all&#xD;
             scheduled visits, treatment plan, laboratory tests, and other study procedures.&#xD;
&#xD;
          3. Participant is available for the entire study period and the participant's&#xD;
             parent(s)/legal guardian can be reached by telephone.&#xD;
&#xD;
          4. Healthy participant as determined by medical history, physical examination, and&#xD;
             judgment of the investigator.&#xD;
&#xD;
          5. Body weight ≥4 kg for participants 2 months of age at the time of randomization.&#xD;
&#xD;
          6. Participants whose parent(s)/legal guardian are capable of giving signed informed&#xD;
             consent, which includes compliance with the requirements and restrictions listed in&#xD;
             the ICD and in this protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior adverse reaction to paracetamol use, including allergic reactions.&#xD;
&#xD;
          2. Participant was born prematurely (&lt;37 weeks of gestation).&#xD;
&#xD;
          3. A previous anaphylactic reaction to any vaccine or vaccine-related component.&#xD;
&#xD;
          4. Bleeding diathesis or condition associated with prolonged bleeding time that would&#xD;
             contraindicate intramuscular injection.&#xD;
&#xD;
          5. A known or suspected defect of the immune system that would prevent an immune response&#xD;
             to the vaccine, such as participants with congenital or acquired defects in B-cell&#xD;
             function, those receiving chronic systemic (oral, intravenous, or intramuscular)&#xD;
             corticosteroid therapy, or those receiving immunosuppressive therapy. Please refer to&#xD;
             the SRM for additional details.&#xD;
&#xD;
          6. History of microbiologically proven disease caused by N meningitidis or Neisseria&#xD;
             gonorrhoeae.&#xD;
&#xD;
          7. Significant neurological disorder or history of seizure (including simple febrile&#xD;
             seizure).&#xD;
&#xD;
          8. Any neuroinflammatory or autoimmune condition, including, but not limited to,&#xD;
             transverse myelitis, uveitis, optic neuritis, and multiple sclerosis.&#xD;
&#xD;
          9. Other acute or chronic medical or psychiatric condition or laboratory abnormality that&#xD;
             may increase the risk of study participation or, in the investigator's judgment, make&#xD;
             the participant inappropriate for the study.&#xD;
&#xD;
         10. Previous vaccination with any meningococcal vaccine. Written vaccination history must&#xD;
             be obtained prior to randomization.&#xD;
&#xD;
         11. For participants 2 months of age, prior vaccination with any of the following licensed&#xD;
             or investigational vaccines: pneumococcal vaccine and hexavalent DTPa-HBV-IPV-Hib or&#xD;
             its component, except for the birth dose of hepatitis B vaccine.&#xD;
&#xD;
         12. Participants receiving any allergen immunotherapy with a nonlicensed product or&#xD;
             receiving allergen immunotherapy with a licensed product and are not on stable&#xD;
             maintenance doses.&#xD;
&#xD;
         13. Receipt of any blood products, including immunoglobulin, before the first study&#xD;
             vaccination.&#xD;
&#xD;
         14. Current chronic use of systemic antibiotics.&#xD;
&#xD;
         15. Participation in other studies involving investigational drug(s) or investigational&#xD;
             vaccine(s) within 28 days prior to study entry and/or during study participation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Months</minimum_age>
    <maximum_age>6 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <phone>1-800-718-1021</phone>
    <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Kinderarztpraxis</name>
      <address>
        <city>Bramsche</city>
        <zip>49565</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Praxis 3Kaesehoch Bönnigheim</name>
      <address>
        <city>Bönnigheim</city>
        <zip>74357</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Lothar Maurer und Dr. Andreas Maurer</name>
      <address>
        <city>Frankenthal</city>
        <zip>67227</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Paediatricum Dr. Wolff</name>
      <address>
        <city>Hagen</city>
        <zip>58093</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dr. med. Dr. rer. nat. Helmut Pabel</name>
      <address>
        <city>Herford</city>
        <zip>32049</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kinderarztpraxis Dr. Karsten Jünger</name>
      <address>
        <city>Herxheim</city>
        <zip>76863</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dr. med Falko Panzer Praxis fuer Kinder und Jugendliche</name>
      <address>
        <city>Mannheim</city>
        <zip>68161</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kinderärztliche Gemeinschaftspraxis Bedikian und Bouikidis</name>
      <address>
        <city>Oberhausen</city>
        <zip>46145</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kinder und Jungendarztpraxis Dr. Horn</name>
      <address>
        <city>Schönau am Königssee</city>
        <zip>83471</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kinderaerztliche Gemeinschaftspraxis Westerholt Matyas</name>
      <address>
        <city>Wolfsburg</city>
        <zip>38448</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>General University Hospital of Larissa</name>
      <address>
        <city>Larissa</city>
        <state>Thessaly</state>
        <zip>41110</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>&quot;Aghia Sophia&quot; Children's Hospital</name>
      <address>
        <city>Athens</city>
        <zip>11527</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>P. &amp; A. Kyriakou Children's Hospital</name>
      <address>
        <city>Athens</city>
        <zip>11527</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University General Hospital &quot;ATTIKON&quot;</name>
      <address>
        <city>Athens</city>
        <zip>12462</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>&quot;Ippokratio&quot; General Hospital of Thessaloniki</name>
      <address>
        <city>Thessaloniki</city>
        <zip>54642</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario Santiago de Compostela</name>
      <address>
        <city>Santiago de Compostela</city>
        <state>A Coruna</state>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Germans Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari General de Catalunya</name>
      <address>
        <city>Sant Cugat del Valles</city>
        <state>Barcelona</state>
        <zip>08195</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Burgos</name>
      <address>
        <city>Burgos</city>
        <state>Castilla Y LEON</state>
        <zip>09006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario HM Puerta del Sur</name>
      <address>
        <city>Móstoles</city>
        <state>Madrid</state>
        <zip>28938</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centro de Salud L'Eliana</name>
      <address>
        <city>L'Eliana</city>
        <state>Valencia</state>
        <zip>46183</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centro de Salud de Paiporta</name>
      <address>
        <city>Paiporta</city>
        <state>Valencia</state>
        <zip>46200</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Vithas Virgen del Mar</name>
      <address>
        <city>Almeria</city>
        <zip>04120</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Marañón</name>
      <address>
        <city>Madrid</city>
        <zip>28009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Clinico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Grupo Pediátrico Uncibay</name>
      <address>
        <city>Malaga</city>
        <zip>29015</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Instituto Hispalense de Pediatria</name>
      <address>
        <city>Sevilla</city>
        <zip>41012</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen Del Rocio</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>FISABIO</name>
      <address>
        <city>Valencia</city>
        <zip>46020</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centro de Salud la Serreria II</name>
      <address>
        <city>Valencia</city>
        <zip>46022</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centro de Salud Nazaret</name>
      <address>
        <city>Valencia</city>
        <zip>46024</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Greece</country>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>https://pmiform.com/clinical-trial-info-request?StudyID=C3511002</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 20, 2020</study_first_submitted>
  <study_first_submitted_qc>November 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 27, 2020</study_first_posted>
  <last_update_submitted>October 25, 2021</last_update_submitted>
  <last_update_submitted_qc>October 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Meningococcal Vaccine</keyword>
  <keyword>Invasive Meningococcal Disease</keyword>
  <keyword>Meningococcal Serogroups A, B, C W and Y</keyword>
  <keyword>MenABCWY Vaccine</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

